Milestone Scientific Q4 2025 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy MLSS?
Source: seekingalpha
- Management Restructuring: CEO Eric Hines, who took over in August 2025, immediately scrutinized company expenditures, cutting non-revenue-generating costs to ensure effective resource utilization, thereby laying a foundation for future growth.
- Revenue Growth Outlook: Management projects total revenue for 2026 to be between $9.8 million and $10.2 million, reflecting double-digit year-over-year growth primarily driven by continued adoption in international markets and dental products, indicating the company's market potential.
- CompuFlo Initiative: Hines emphasized that the CompuFlo system will be a key growth driver, with expected contributions of $500,000 to $600,000 in 2026, representing approximately a 400% increase over 2025, which will significantly enhance the company's competitive position in the market.
- Cash Flow Target: Management has set a goal to achieve cash flow breakeven by early 2027, and combined with cost control measures from 2025, this is expected to significantly improve operating leverage and reduce cash burn, enhancing the company's financial stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLSS
Wall Street analysts forecast MLSS stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.336
Low
1.00
Averages
1.00
High
1.00
Current: 0.336
Low
1.00
Averages
1.00
High
1.00
About MLSS
Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Milestone Scientific Reports Earnings Highlights
- Significant Cost Reduction: Milestone Scientific Inc (MLSS) reduced operating expenses by approximately $1.3 million, or over 30% year-over-year, which not only significantly narrowed losses but also provided more flexibility for future investments.
- CompuFlow Revenue Doubling: CompuFlow medical revenue more than doubled year-over-year, reflecting early-stage adoption and growing interest from clinicians, which is expected to lay the groundwork for future revenue growth.
- 2026 Revenue Guidance Reaffirmed: The company reaffirmed its 2026 total revenue guidance in the range of $9.8 million to $10.2 million, representing double-digit year-over-year growth, demonstrating management's confidence in future performance.
- Middle East Order Delays Impact: Revenue was impacted by the inability to ship approximately $200,000 in booked orders due to ongoing global conflict, although most of these orders have now shipped in Q2, indicating short-term pressure on sales.
See More
Milestone Scientific Releases FY26 Outlook with Revenue Plan
- Earnings Report: Milestone Scientific reported a Q1 GAAP EPS of -$0.01, aligning with expectations, but revenue of $2.16 million fell short by $0.34 million, reflecting challenges in revenue growth amid a 3.1% year-over-year decline.
- Cash Position: As of March 31, 2026, Milestone Scientific had approximately $1.2 million in cash, a slight increase from $1.1 million on December 31, 2025, indicating improved liquidity management, though cash flow remains a concern.
- Future Outlook: The company projects FY26 revenue between $9.8 million and $10.2 million, targeting cash flow breakeven by early 2027, which demonstrates management's confidence in future growth despite current challenges.
- Market Reaction: Although the company missed revenue estimates, its outlook and cash flow targets may alleviate some investor concerns, reflecting management's positive expectations regarding market demand.
See More
Milestone Scientific Expands CompuFlo Business with Increased Physician Engagement
- Advisor Program Driving Utilization: Since launching the CompuFlo® Advisor Program in February 2026, Milestone has onboarded physician advisors and initiated procedural use across key Medicare Administrative Contractor jurisdictions, significantly enhancing physician engagement and real-world data generation, which is expected to drive future revenue growth.
- Sales Network Expansion: Milestone is expanding its national sales footprint through a growing network of sales consultant partners across NJ, NY, PA, and FL, targeting pain clinics and hospitals, thereby enhancing market coverage and promoting device utilization.
- Academic Collaboration Enhancing Clinical Validation: The company collaborates with leading academic institutions such as the University of Texas, University of Kansas, and University of Minnesota to support clinical validation and training, aiming to improve clinical acceptance of CompuFlo® and drive broader market application.
- Building Foundation for Long-Term Growth: Milestone focuses on expanding physician utilization and geographic coverage while driving recurring revenue growth, ensuring a solid commercial infrastructure to support future commercialization efforts.
See More
Milestone Scientific Closes $2.15 Million Financing Round
- Financing Amount: Milestone Scientific has successfully closed a $2.15 million private placement, with an additional potential $2.69 million if cash warrants are fully exercised, thereby strengthening the company's balance sheet to meet increasing demand across its product platforms.
- Investor Participation: The financing saw participation from long-term investors and board members, including CEO Eric Hines, who invested $150,000 in cash, reflecting strong endorsement of the company's technology and strategic direction.
- Use of Funds: The raised capital will be allocated towards scaling investments in sales, inventory, and digital marketing while maintaining cost discipline, aiming to enhance the company's competitive position in the medical injection technology sector.
- Compliance and Transparency: This private placement was conducted in accordance with NYSE American rules and closed on April 20, 2026, with transaction details disclosed in the company's 8-K report filed with the SEC, ensuring comprehensive investor understanding of the financing terms.
See More
Milestone Scientific Reports Q4 2025 Earnings and Future Guidance
- Revenue Growth: Q4 2025 revenue reached $2.1 million, a 2.2% increase from $2 million in Q4 2024, indicating stability in the market despite modest growth, which may present future opportunities.
- Improved Operating Loss: The operating loss for Q4 2025 was $1.1 million, an 89% improvement from $2 million in Q4 2024, demonstrating significant progress in cost control and operational efficiency.
- Future Guidance: The 2026 revenue guidance is set between $9.8 million and $10.2 million, reflecting expectations of double-digit year-over-year growth, showcasing the company's confidence in future market demand and strategic positioning.
- International Market Expansion: Milestone Scientific's dental business is gaining traction in countries like Japan, India, and Mexico, indicating the company's proactive approach to seeking growth opportunities in international markets to enhance its global competitiveness.
See More
Milestone Scientific Q4 2025 Earnings Call Insights
- Management Restructuring: CEO Eric Hines, who took over in August 2025, immediately scrutinized company expenditures, cutting non-revenue-generating costs to ensure effective resource utilization, thereby laying a foundation for future growth.
- Revenue Growth Outlook: Management projects total revenue for 2026 to be between $9.8 million and $10.2 million, reflecting double-digit year-over-year growth primarily driven by continued adoption in international markets and dental products, indicating the company's market potential.
- CompuFlo Initiative: Hines emphasized that the CompuFlo system will be a key growth driver, with expected contributions of $500,000 to $600,000 in 2026, representing approximately a 400% increase over 2025, which will significantly enhance the company's competitive position in the market.
- Cash Flow Target: Management has set a goal to achieve cash flow breakeven by early 2027, and combined with cost control measures from 2025, this is expected to significantly improve operating leverage and reduce cash burn, enhancing the company's financial stability.
See More
Milestone Scientific Reports Earnings Highlights
- Significant Cost Reduction: Milestone Scientific Inc (MLSS) reduced operating expenses by approximately $1.3 million, or over 30% year-over-year, which not only significantly narrowed losses but also provided more flexibility for future investments.
- CompuFlow Revenue Doubling: CompuFlow medical revenue more than doubled year-over-year, reflecting early-stage adoption and growing interest from clinicians, which is expected to lay the groundwork for future revenue growth.
- 2026 Revenue Guidance Reaffirmed: The company reaffirmed its 2026 total revenue guidance in the range of $9.8 million to $10.2 million, representing double-digit year-over-year growth, demonstrating management's confidence in future performance.
- Middle East Order Delays Impact: Revenue was impacted by the inability to ship approximately $200,000 in booked orders due to ongoing global conflict, although most of these orders have now shipped in Q2, indicating short-term pressure on sales.
See More
Milestone Scientific Releases FY26 Outlook with Revenue Plan
- Earnings Report: Milestone Scientific reported a Q1 GAAP EPS of -$0.01, aligning with expectations, but revenue of $2.16 million fell short by $0.34 million, reflecting challenges in revenue growth amid a 3.1% year-over-year decline.
- Cash Position: As of March 31, 2026, Milestone Scientific had approximately $1.2 million in cash, a slight increase from $1.1 million on December 31, 2025, indicating improved liquidity management, though cash flow remains a concern.
- Future Outlook: The company projects FY26 revenue between $9.8 million and $10.2 million, targeting cash flow breakeven by early 2027, which demonstrates management's confidence in future growth despite current challenges.
- Market Reaction: Although the company missed revenue estimates, its outlook and cash flow targets may alleviate some investor concerns, reflecting management's positive expectations regarding market demand.
See More
Milestone Scientific Expands CompuFlo Business with Increased Physician Engagement
- Advisor Program Driving Utilization: Since launching the CompuFlo® Advisor Program in February 2026, Milestone has onboarded physician advisors and initiated procedural use across key Medicare Administrative Contractor jurisdictions, significantly enhancing physician engagement and real-world data generation, which is expected to drive future revenue growth.
- Sales Network Expansion: Milestone is expanding its national sales footprint through a growing network of sales consultant partners across NJ, NY, PA, and FL, targeting pain clinics and hospitals, thereby enhancing market coverage and promoting device utilization.
- Academic Collaboration Enhancing Clinical Validation: The company collaborates with leading academic institutions such as the University of Texas, University of Kansas, and University of Minnesota to support clinical validation and training, aiming to improve clinical acceptance of CompuFlo® and drive broader market application.
- Building Foundation for Long-Term Growth: Milestone focuses on expanding physician utilization and geographic coverage while driving recurring revenue growth, ensuring a solid commercial infrastructure to support future commercialization efforts.
See More
Milestone Scientific Closes $2.15 Million Financing Round
- Financing Amount: Milestone Scientific has successfully closed a $2.15 million private placement, with an additional potential $2.69 million if cash warrants are fully exercised, thereby strengthening the company's balance sheet to meet increasing demand across its product platforms.
- Investor Participation: The financing saw participation from long-term investors and board members, including CEO Eric Hines, who invested $150,000 in cash, reflecting strong endorsement of the company's technology and strategic direction.
- Use of Funds: The raised capital will be allocated towards scaling investments in sales, inventory, and digital marketing while maintaining cost discipline, aiming to enhance the company's competitive position in the medical injection technology sector.
- Compliance and Transparency: This private placement was conducted in accordance with NYSE American rules and closed on April 20, 2026, with transaction details disclosed in the company's 8-K report filed with the SEC, ensuring comprehensive investor understanding of the financing terms.
See More
Milestone Scientific Reports Q4 2025 Earnings and Future Guidance
- Revenue Growth: Q4 2025 revenue reached $2.1 million, a 2.2% increase from $2 million in Q4 2024, indicating stability in the market despite modest growth, which may present future opportunities.
- Improved Operating Loss: The operating loss for Q4 2025 was $1.1 million, an 89% improvement from $2 million in Q4 2024, demonstrating significant progress in cost control and operational efficiency.
- Future Guidance: The 2026 revenue guidance is set between $9.8 million and $10.2 million, reflecting expectations of double-digit year-over-year growth, showcasing the company's confidence in future market demand and strategic positioning.
- International Market Expansion: Milestone Scientific's dental business is gaining traction in countries like Japan, India, and Mexico, indicating the company's proactive approach to seeking growth opportunities in international markets to enhance its global competitiveness.
See More
Milestone Scientific Q4 2025 Earnings Call Insights
- Management Restructuring: CEO Eric Hines, who took over in August 2025, immediately scrutinized company expenditures, cutting non-revenue-generating costs to ensure effective resource utilization, thereby laying a foundation for future growth.
- Revenue Growth Outlook: Management projects total revenue for 2026 to be between $9.8 million and $10.2 million, reflecting double-digit year-over-year growth primarily driven by continued adoption in international markets and dental products, indicating the company's market potential.
- CompuFlo Initiative: Hines emphasized that the CompuFlo system will be a key growth driver, with expected contributions of $500,000 to $600,000 in 2026, representing approximately a 400% increase over 2025, which will significantly enhance the company's competitive position in the market.
- Cash Flow Target: Management has set a goal to achieve cash flow breakeven by early 2027, and combined with cost control measures from 2025, this is expected to significantly improve operating leverage and reduce cash burn, enhancing the company's financial stability.
See More
